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Background: Relapsing Plasmodium vivax infection results in significant morbidity for the individual and is a key
factor in transmission. Primaquine remains the only licensed drug for prevention of relapse. To minimize relapse
rates, treatment guidelines have recently been revised to recommend an increased primaquine dose, aiming to
achieve a cumulative dose of ≥6 mg/kg, i.e. ≥420 mg in a 70 kg patient. The aims of this study were to
characterize the epidemiology of P. vivax infection imported into Queensland Australia, to determine the rates of
relapse, to investigate the use of primaquine therapy, and its efficacy in the prevention of relapse.
Methods: A retrospective study was undertaken of laboratory confirmed P. vivax infection presenting to the two
major tertiary hospitals in Queensland, Australia between January 1999 and January 2011.
Primaquine dosing was classified as no dose, low dose (<420 mg), high dose (≥420 mg), or unknown. The dose of
primaquine prescribed to patients who subsequently relapsed that prescribed to patients who did not relapse.
Results: Twenty relapses occurred following 151 primary episodes of P. vivax infection (13.2%). Relapses were
confirmed among 3/21 (14.2%), 9/50 (18.0%), 1/54 (1.9%) and 7/18 (38.9%) of patients administered no dose, low
dose, high dose and unknown primaquine dose respectively. High dose primaquine therapy was associated with a
significantly lower rate of relapse compared to patients who were prescribed low dose therapy (OR 11.6, 95% CI
1.5-519, p = 0.005).
Conclusions: Relapse of P. vivax infection is more likely in patients who received low dose primaquine therapy. This
study supports the recommendations that high dose primaquine therapy is necessary to minimize relapse of
P. vivax malaria.
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Although Australia was declared malaria free in 1981,
cases of malaria continue to be imported into the coun-
try, with P. vivax being the most common causative spe-
cies [1,2]. The state of Queensland reports the greatest
numbers, at a rate nearly double that of the Australian
average [2]. Most of these infections are acquired in
Oceania, with Papua New Guinea (PNG) being the
source of over two-thirds of malaria imported into
Queensland [1,3,4]. Of note, over the past decade there
has been a gradual reduction in notifications of malaria* Correspondence: j.mccarthy@uq.edu.au
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reproduction in any medium, provided the orinto Australia, with laboratory diagnoses in the state of
Queensland falling from 504 in 2000 to 146 in 2011
(McCarthy, unpublished).
Primaquine, an 8-aminoquinoline, has been in wide-
spread clinical use for over 60 years, and remains the
only treatment option for eradication of liver hypno-
zoites and, therefore the prevention of relapses [5,6].
The mechanism of action of primaquine is poorly under-
stood [6,7]. It is widely available, affordable and is gener-
ally well-tolerated [8]. Gastrointestinal symptoms, while
common can be minimized by taking the medication
with food or by splitting doses [9]. Primaquine therapy
can result in severe acute haemolysis in patients with
glucose-6-phosphate dehydrogenase (G6PD) deficiency.
It is, therefore, contraindicated in patients with G6PD
deficiency and pregnancy (due to the unknown G6PDl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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imposes significant costs and logistical problems, espe-
cially in resource poor settings, where it inhibits wide-
spread use.
The efficacy of primaquine therapy in preventing
relapses is difficult to define, with studies confounded by
uncertain compliance, recrudescence and re-infection
[6,10]. To minimize these confounding effects, assess-
ment of primaquine efficacy can be most readily studied
in travellers returning to developed non-malarious
regions. There is, however, a paucity of studies from
these regions that have specifically focused on prima-
quine use and dosing.
Traditionally, the recommended dose of primaquine
has been 15 mg/day for 2 weeks. The rationale for the
licensing of this dose was based predominantly on safety
– 15 mg/day could be administered to African-
American soldiers, returning from the Korean war, with-
out concerns of life-threatening haemolysis [7]. The
efficacy of primaquine therapy for clearance of hepatic
stages of P. vivax is considered to vary according to the
geographical area of acquisition [10]. Although treat-
ment failures have been documented from all geographic
regions, generally poorer responses have been observed
among patients acquiring their malaria from SE Asia
and Oceania [5,10], with the so-called Chesson strain
being documented to be relatively resistant to prima-
quine [5]. Over the past decade, there has been increas-
ing evidence that higher cumulative doses of primaquine
are required to reduce treatment failures [11-13], and as
a consequence the recommended cumulative dose of
primaquine has been recently revised upwards to 6 mg/kg
(i.e. 30 mg/day for 14 days in a 70 kg patient) [5,7]. This
high dose primaquine regimen is now recommended as
standard of care in an increasing number of guidelines
[14-16]. Since 2010, Australian guidelines have been
recommending≥ 6 mg/kg (i.e. 30 mg for 14 days in a
≤70 kg patient) [16]. The latest WHO treatment guide-
lines currently recommend high dose therapy only for
patients who acquire their infection from SE Asia and
Oceania [17].
The aims of this study were to characterize the epi-
demiology of P. vivax infection currently imported into
Queensland Australia, to determine the rates of relapse,
to investigate the use of primaquine therapy and its effi-
cacy in the prevention of relapse.
Methods
A retrospective review of P. vivax malaria cases was per-
formed in the two major adult tertiary hospitals in
south-east Queensland (Princess Alexandra Hospital and
Royal Brisbane and Women’s Hospital). Cases of P. vivax
infection were identified by computerized search of the
state-wide pathology records from January 1999 toJanuary 2011. Cases were defined as P. vivax malaria
based either on blood film or a PCR test.
To optimize ascertainment of cases and relapses, col-
lateral information was collected from the Queensland
Public Health Malaria Register, Sullivan and Nicolaides
Pathology (one of the two major private pathology la-
boratories in Queensland) and from the Queensland
Malarial Reference Laboratory (QMRL). Since 1999, all
public hospitals and both major private laboratories in
Queensland have routinely referred all positive blood
films to QMRL for confirmatory slide verification. All
available medical charts were reviewed, data were de-
identified and entered into a Microsoft Excel spread-
sheet (v2003). Data collected included epidemiological
data, travel history, severity of illness, diagnosis, treat-
ment, primaquine therapy and outcomes. Chemo-
prophylaxis regimens were considered appropriate if
concordant with Australian guidelines [16], which are
closely aligned to other international guidelines.
A relapse was defined as a subsequent infection with no
return travel to a malaria endemic country in the interval
between first and subsequent episode, or P. vivax infection
after receiving primaquine therapy as presumptive anti-
relapse therapy (PART, otherwise known as terminal
prophylaxis). If a patient had received chloroquine therapy
for treatment of P. vivax infection, incident malaria within
35 days could either be due to relapse or recrudescence or
both [18]. The authors were unable to classify the subse-
quent infection in these patients. For the purpose of this
study, in order to determine the adequacy of primaquine
at preventing relapses, they were defined as having recru-
descent parasitaemia and excluded from further analysis.
Re-infection was defined as a second infection that oc-
curred following subsequent travel to an endemic country.
As patients’ weights were not universally recorded, a
weight of 70 kg was empirically applied to all patients.
For the purpose of the study, primaquine dosing was
defined as no dose, low dose (<420 mg; assuming a
weight of 70 kg), high dose (≥420 mg; equivalent to
6 mg/kg in a 70 kg patient) or unknown dose. Patients
were censored with no further statistical analysis after
their first relapse to prevent confounding by the cumula-
tive effect of repeated primaquine dosing.
Statistical analysis was performed using Microsoft
Excel (v2003) and Stata V11. Categorical data was ana-
lysed using both Fischer’s exact tests with two tailed
p-values and calculation of Odds ratio (OR) with 95%
confidence intervals (CI), and is logistic regression mod-
els where appropriate. Nonparametric continuous data
was analysed using Wilcoxon rank-sum test. P-value of
less than 0.05 was deemed to be statistically significant.
Ethics approval was gained from the responsible ethics
committees at both institutions (HREC/10/QPAH/338,
HREC/10/QRBW/361).
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A patient flow diagram is shown in Figure 1. Plasmodium
vivax infection was identified in 172 patients between Janu-
ary 1999 and January 2011. The medical records of 29
patients had been destroyed, and so these cases were
excluded from the analysis. All remaining patients (n=143)
were included in the study. A total of 184 P. vivax infec-
tions were evaluated, of which 151 were episodes of pri-
mary P. vivax infection. Eight (5.3%) second infections
occurred following a subsequent visit to a malaria endemic
region, and were classified as reinfections. Following
chloroquine therapy, five (3.3%) second infections occurred
within 35 days of the initial diagnosis (days 20, 20, 22, 23,
27). All five patients had travelled to PNG, had received
chloroquine therapy, and had a recurrent P. vivax diagnosis
confirmed. As it was not possible to determine whe-
ther their recurrent infection represented recrudescent
chloroquine-resistant P. vivax infection or relapse, for the
purpose of this study their recurrent infections were classi-
fied as recrudescent parasitaemia. Three patients had a sec-
ond infection for which no further clinical information was
available; these infections could not be classified and were
excluded from further analysis. Twenty (13.2%) relapses
were recorded, including two patients who had received
PART. Four (2.7%) patients subsequently had a second re-
lapse and one (0.7%) patient had a third relapse. Mixed
infections occurred in 7.3% (n=11) of cases, with ten casesFigure 1 Patient flow diagram showing subsequent infection outcom
subjects with reinfections. • excluded from analysis. } includes 2 patients wof P. falciparum infection and one case of Plasmodium
malariae infection.
Patient demographics are shown in Table 1. Over three
quarters of P. vivax infections were imported from
Oceania (n = 115, 76.2%). The most commonly visited
countries were PNG (n = 91, 60.3%), followed by the
Solomon Islands (n = 15, 9.9%), India (n = 14, 9.3%),
Indonesia (n = 10, 6.6%) and Vanuatu (n = 8, 5.3%). The
main reasons for travel were recorded as business
(n =47, 31.1%), tourism (n=30, 19.9%), and visiting friends
or relatives (VFR) (n=28, 18.5%). Less than half of the
patients were recorded as having taken chemoprophylaxis
(n=64, 42.4%). For those who received chemoprophylaxis,
doxycycline was the preferred agent (n= 39, 60.9%). The
chemoprophylactic regimen was judged inappropriate in 6
(9.4%) cases; all entailed the prescription of chloroquine in
patients travelling to Oceania.
The median time from arrival into Australia until
diagnosis of infection was one month, with a range of
0 days to 14 months (IQR 0.4-2.6 months). P. Vivax
malaria was a benign infection in the majority of the
patients, with no recorded deaths. Two (n = 2/179,
1.1%) infections were defined as severe [17]–one pa-
tient had severe anaemia and required a blood trans-
fusion, while one patient had mixed infection with
P. falciparum and required an ICU admission due to
multiple convulsions and hypernatremia.es. Percentages based on number of primary infections. † includes 8
ho received PART.
Table 1 Patient characteristics
N (%)* Median IQR (range)
Age – years 32 23-47 (13–76)
Duration of trip – months (n = 66) 1 0.8-3 (0.1-19)
Weight – kg (n = 43) 72 66-89 (52–104)
Male Gender 105 (69.5)




Foreign visitors 10 (6.6)
Not Stated 18 (11.9)
Geographic region visited Oceania 115 (76.2%)
Indian subcontinent 14 (9.3%)
SE Asia 11 (7.3%)
Africa 6 (4.0%)
S. America 2 (1.3%)
Multiple 2 (1.3%)
Unknown 1 (0.7%)
Chemoprophylaxis Yes 64 (42.4)
No 77 (51.0)
Not recorded 10 (6.6)





Combination of agents 2 (3.1)
Agent not known 9 (14.0)
Mixed infection P. falciparum 10 (6.6)
P. malariae 1 (0.6)







Change in regimen 18 (10.5)
Unknown 9 (5.0)
*Percentages based on number of primary P. Vivax infections, unless stated otherwise.
^VFR – visiting friends and relatives.
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tially managed as an inpatient, with a median length of
stay of 1 day (IQR 1–3). Chloroquine was the preferred
initial treatment agent (n = 115, 64.2%). Artemisinin
combination treatment regimens were used in 12 (6.7%)
infections, and were used with increasing frequencyfrom 2008 onwards. A change of treatment regimen oc-
curred in 18 (10.1%) cases. Reasons reported for change
in therapy included poor clinical response, or clinician
preference. Clinical failure of chloroquine therapy was
noted in 6/115 (5.2%) infections – all patients acquired
malaria from PNG or nearby islands, and had prolonged
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cessitating change in therapy which was followed by sub-
sequent clinical improvement. No severe adverse effects
of therapy were noted.
The median time between infection and relapse was
78 days (IQR 60–119, range 27–399). Although not sta-
tistically significant, there was a trend for increased inci-
dence of relapse in patients returning from Oceania
(n = 18/107, 16.8% vs. n = 2/36 5.6% rest of the world,
OR 3.4 CI 0.75-31.9, p = 0.09).
Various primaquine regimens were prescribed (od/bd/
tds/qid, 7.5 mg/15 mg/22.5 mg/30 mg, 1 week/2 weeks/
3 weeks). Over 75% (n = 114, 79.7%) of patients received
primaquine therapy after their initial infection. Prima-
quine was not given to 21 subjects for the following rea-
sons: planned return to an endemic country (n = 13,
61.9%), failure to attend clinic (n = 4, 19.0%), pregnancy
(n = 1, 4.8%), allergy (n = 1, 4.8%), mistake – film thought
to be P. falciparum (n = 1, 4.8%) and unknown (n = 1,
4.8%). Primaquine therapy was well tolerated, with no
major adverse events or drug discontinuations recorded.
G6PD status was not assessed in 9 (7.9%) patients des-
pite them receiving primaquine. No cases of G6PD defi-
ciency were identified.
Primaquine dosing and outcomes are shown in Table 2.
The dose of primaquine prescribed was not documented
in 18 (12.6%) infections. The median cumulative pre-
scribed dose of primaquine was 315 mg (IQR 210-
420 mg). The cumulative dose of primaquine therapy in
patients who relapsed was lower compared to the dose
received by patients who did not relapse (median
210 mg, IQR 210-315 mg vs. median 315 mg, IQR 210–
420, p = 0.01). Patients who received low dose prima-
quine therapy were significantly more likely to relapse
compared to patients who received high dose prima-








Primaquine N (%) N (%) N (%)
Yes 114 79.7 16 80.0 98 79.7
Nil 21 14.7 3 15.0 18 14.6
Unknown 8 5.6 1 5.0 7 5.7
Primaquine dose
Nil 21 14.7 3 15.0 18 14.6
Low (<420 mg) 50 35.0 9† 45.0 41† 33.3
High (≥420 mg) 54 37.8 1† 5.0 53† 43.1
Unknown 18 12.6 7 35.0 11 8.9
Dosage (mg) median (IQR) median (IQR) median (IQR)
315 (210–420) 210 (210–315) 315 (210–420)
†(OR 11.6, 95% CI 1.5-519, p = 0.005).Discussion
Accurate ascertainment of relapse rates in P. vivax mal-
aria is well recognized to be difficult, with studies often
compromised by under-reporting and short follow-up
periods. In this study, the computerized state-wide path-
ology services, and the compulsory reporting of all cases
to the Queensland Malarial Reference Laboratory made
it possible to confidently identify subsequent P. vivax
infections occurring within the State. Incomplete ascer-
tainment of relapses remains possible, as a patient may
have relapsed whilst interstate or abroad. Other limita-
tions of the study include its retrospective design,
resulting in potential loss of clinical information, non-
standardized treatment regimens, and no active follow
up with consequent unknown adherence to treatment.
Despite these limitations, the relapse rate of 18.0% fol-
lowing low dose primaquine therapy is similar to what
has been reported in other studies of imported P. vivax
malaria [11,19-25]. These data are also in agreement
with other published studies that have reported a signifi-
cantly lower frequency of relapse with increased prima-
quine dosing [6,9,11,13,17], and support the hypothesis
that relapse rates are low (<5%) if high dose primaquine
therapy is prescribed. Unfortunately, the implementation
of evidence-based dose regimens of primaquine in en-
demic countries remain hampered by widespread use of,
low dose, short course therapies for which a paucity of
efficacy data are available [13].
The data support the recommendation that, in order
to minimize treatment failure, it is important to pre-
scribe the target dose based on patient weight [11]. Al-
though weights were not available for all patients, our
estimated weight of 70 kg was similar to the median
weight of 72 kg of patients whose weight was recorded
(IQ R66-89, n = 43). Thus, 420 mg of primaquine, which
is equivalent to a dose of 6 mg/kg, would be considered
appropriate as a high dose regimen for half of the study
population.
Although compliance could not be assessed in this
study, the importance of compliance in reducing relapses
is well documented [8]. Compliance may be improved
by providing patients with education regarding the need
for primaquine as well as regular review. It is also pos-
sible that compliance may be improved by using a high
dose abbreviated regimen, such as 30 mg twice daily for
1 week, in patients who are not G6PD deficient [5].
Further studies are required to determine if high dose
therapy is the optimal dose of primaquine. Ideally, a ran-
domized controlled trial would be performed, but this is
unlikely to be undertaken due to logistic constraints.
Thus, retrospective studies, such as this study, may be
an important strategy to gather further information.
Only 3 patients of 21 (14.3%) who were not prescribed
primaquine relapsed. As most patients acquired their
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what may have been expected. It is, however, not signifi-
cantly different to the frequency of recurrence in this
study among patients who were prescribed low dose
primaquine therapy (3/21 [14.3%] vs 9/50 [18%]). Fur-
ther, most of the patients who did not receive prima-
quine were planning to return to an endemic country
soon, or failed to attend clinic (n = 17, 80.1%). It is,
therefore, possible that incomplete ascertainment of
relapses in this group may have resulted in a lower
reported frequency of recurrence.
There are a few published case reports of relapses des-
pite patients being prescribed 420 mg of primaquine
[12,26]. These cases are clustered around Southeast Asia
and Oceania – two cases from Indonesia and each
respectively from Vanuatu and the Solomon Islands. In
none of these three cases nor in the single case reported
in this study was weight-based dosing and/or compli-
ance reported. This case, as with the three other cases
described, does not satisfactorily document either
weight-based dosing and/or compliance. Subsequent
primaquine treatment of these patients varied - one pa-
tient refused further primaquine after his 3rd relapse, the
patient in this study received 315 mg, two patients
received 840 mg (60 mg/day for 14 days), all without
complication or subsequent relapse. The most appropri-
ate management approach for patients who fail high
dose therapy remains unclear. Further studies are
required to determine the ongoing adequacy of high
dose primaquine therapy and the potential development
of primaquine resistance. If treatment failures are subse-
quently identified, such cases need to be further evalu-
ated in respect to causes, treatment and prevention.
The majority of P. vivax infections in Australia are
imported from Oceania, especially PNG. Although not
statistically significant, our study supports the previously
reported increased risk of relapse if P. vivax is acquired
in Oceania [19,25,27].
Conclusion
This study shows that high doses of primaquine
(≥420 mg) are associated with lower rates of relapse of
P. vivax infection, and supports current treatment guide-
lines recommending ≥6 mg/kg (i.e. 30 mg/kg for 14 days
in a ≤70 kg patient) total dose.
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